Samsung Biologics
Incheon, KR
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (20)
Quick Facts: Samsung Biologics
- Signal Score
- 59.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Incheon, KR
- Modalities
- Cell Therapy, mRNA
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed — 3 partnership announcements in press
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 3 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
Financial Stability
60.0
M&A activity detected (1 articles)
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
M&A activity detected (1 articles)
Capacity
58.0
Active facility expansion (2 articles)
Strong partnership activity (3 articles)
Sites: Incheon, KR
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press20 articles
Active facility expansion (2 articles)
Strong partnership activity (3 articles)
Recent News 20 articles
Samsung Biologics warns of headwinds, pushes expansion as Epis eyes new drugs - koreabiomed.com
Samsung Biologics warns of headwinds, pushes expansion as Epis eyes new drugs koreabiomed.com
Samsung Biologics shareholders approve third term for CEO John Rim, boosting CDMO push - aju press
Samsung Biologics shareholders approve third term for CEO John Rim, boosting CDMO push aju press
Rapid Micro Biosystems expands Samsung Biologics partnership - Cleanroom Technology
Rapid Micro Biosystems expands Samsung Biologics partnership Cleanroom Technology
Samsung Biologics tops capacity as China CDMOs surge, Japan drops - CHOSUNBIZ - Chosunbiz
Samsung Biologics tops capacity as China surges, Japan’s Fujifilm drops - CHOSUNBIZ Chosunbiz
Samsung Biologics Co Ltd Stock (ISIN: KR7207940008) Faces Capacity Expansion Pressures Amid Biotech - AD HOC NEWS
Samsung Biologics Co Ltd Stock (ISIN: KR7207940008) Faces Capacity Expansion Pressures Amid Biotech AD HOC NEWS
Samsung Biologics Co Ltd Stock (ISIN: KR7207940008) Faces Capacity Expansion Pressures Amid Biotech - AD HOC NEWS
Samsung Biologics Co Ltd Stock (ISIN: KR7207940008) Faces Capacity Expansion Pressures Amid Biotech AD HOC NEWS
Samsung Biologics signs $189 million drug manufacturing contract with European partner - Korea JoongAng Daily
Samsung Biologics signs $189 million drug manufacturing contract with European partner Korea JoongAng Daily
Samsung Biologics collaborates with Lilly to establish new gateway labs site in Korea - BioSpectrum Asia
Samsung Biologics collaborates with Lilly to establish new gateway labs site in Korea BioSpectrum Asia
Samsung Biologics showcases CDMO capabilities in Singapore - The Korea Herald
Samsung Biologics showcases CDMO capabilities in Singapore The Korea Herald
Samsung Biologics showcases CDO platforms and wins award at BMA 2026 - koreabiomed.com
Samsung Biologics showcases CDO platforms and wins award at BMA 2026 koreabiomed.com
Samsung Biologics Showcases CDMO Platform at BMA 2026, Wins CMO Award - aju press
Samsung Biologics Showcases CDMO Platform at BMA 2026, Wins CMO Award aju press
Samsung Biologics Showcases CDMO Capabilities at 'BMA 2026' - 아시아경제
Samsung Biologics Showcases CDMO Capabilities at 'BMA 2026' 아시아경제
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform - Yahoo Finance
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform Yahoo Finance
Rapid Micro Biosystems Receives Multi-System Order from Samsung Biologics to Expand Growth Direct Platform for Microbial Quality Control Automation - Quiver Quantitative
Rapid Micro Biosystems Receives Multi-System Order from Samsung Biologics to Expand Growth Direct Platform for Microbial Quality Control Automation Quiver Quantitative
Samsung Biologics : 2025 Business Report - marketscreener.com
Samsung Biologics : 2025 Business Report marketscreener.com
Samsung Biologics taps automation to speed safety checks on medicines - Stock Titan
Samsung Biologics taps automation to speed safety checks on medicines Stock Titan
Eli Lilly, Samsung Biologics Form Alliance to Nurture Korean Biotech Startups - 서울경제신문
Eli Lilly, Samsung Biologics Form Alliance to Nurture Korean Biotech Startups 서울경제신문
Lilly, Samsung Biologics Form Alliance to Incubate Korean Biotech Ventures - 서울경제신문
Lilly, Samsung Biologics Form Alliance to Incubate Korean Biotech Ventures 서울경제신문
Samsung Biologics, Eli Lilly to build biotech innovation hub in Korea - The Korea Herald
Samsung Biologics, Eli Lilly to build biotech innovation hub in Korea The Korea Herald
Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea - PR Newswire
Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea PR Newswire
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: